Why the study?
Heart failure guideline recommendations mostly do not differentiate by sex despite biological differences affecting drug pharmacokinetics, pharmacodynamics, and trial representation, highlighting the need for sex-specific treatment guidelines.
Answers are grounded in this paper and cite their sources.
This review emphasizes the critical need for sex-specific treatment guidelines in heart failure due to significant biological and pharmacological differences between men and women.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: